Literature DB >> 21220371

High risk of peripheral arterial disease in the United Kingdom: 2-year results of a prospective registry.

Gerard Stansby1, Rebecca Mister, Gerry Fowkes, Michael Roughton, Fiona Nugara, Julie Brittenden, Andrew Bradbury, Simon Ashley, Cliff Shearman, Ray Hannon, Marcus Flather.   

Abstract

We report a prospective 2-year, multicenter study of patients presenting with intermittent claudication (IC; ankle brachial blood pressure index, ABPI ≤ 0.9). Mean age of the 473 patients enrolled was 68 years, 20% were diabetics, 30% had prior symptomatic coronary heart disease (CHD), 7% had prior stroke, and 39% were current smokers. At baseline, 26.2% of patients had BP ≤ 140/85 mm Hg or lower and at 2 years this figure was 32.5% (P = .01). Current smokers had fallen to 27% (from 39%) at 2 years (P < .001). Use of antiplatelet agents, statins, and angiotensin converting enzyme inhibitors increased significantly during the course of the study as did claudication distance. Death and the composite of death, stroke or myocardial infarction (MI), occurred in 8.4% and 11.6% of patients, respectively. Prognosis was worse in patients with prior history of CHD, older age, those with diabetes and a lower ABPI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220371     DOI: 10.1177/0003319710387917

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

1.  Assessment of Carotid Artery Stenosis and the Use of Statins.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2015-06-05

Review 2.  Intravascular brachytherapy for peripheral vascular disease.

Authors:  Alina Andras; Monica Hansrani; Marlene Stewart; Gerard Stansby
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08

Review 3.  Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review.

Authors:  Rupert Bauersachs; Uwe Zeymer; Jean-Baptiste Brière; Caroline Marre; Kevin Bowrin; Maria Huelsebeck
Journal:  Cardiovasc Ther       Date:  2019-11-26       Impact factor: 3.023

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.